Coherus Oncology Inc (CHRS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
| 12-2000 | |
| Sales | 1,607,079 |
| Cost of Goods | 1,134,554 |
| Gross Profit | 472,525 |
| Operating Expenses | 387,837 |
| Operating Income | 85,242 |
| Interest Expense | 8,894 |
| Other Income | 8,304 |
| Pre-tax Income | 84,652 |
| Income Tax | 33,014 |
| Net Income Continuous | 51,638 |
| Net Income Discontinuous | -540 |
| Net Income | $51,098 |
| EBITDA(a) | $85,242 |